What's Happening?
AstraZeneca is advancing its oral GLP-1 agonist, elecoglipron, into a phase 3 program targeting obesity and type 2 diabetes. This follows promising results from phase 2b trials, VISTA and SOLSTICE, presented at the ADA congress in New Orleans. The VISTA trial showed
significant weight reductions in adults with obesity, with up to 11.8% weight loss at 36 weeks for the highest dose group. The SOLSTICE trial demonstrated a reduction in A1C levels by up to 1.9% in participants with type 2 diabetes, with a notable percentage achieving recommended blood glucose targets. The safety profile was consistent with the GLP-1 receptor agonist class, with gastrointestinal side effects being the most common. AstraZeneca plans to include EMBOLD and ELUMINATE trials in its phase 3 program, focusing on long-term cardiovascular and kidney outcomes.
Why It's Important?
The development of elecoglipron represents a significant step in addressing obesity and type 2 diabetes, conditions affecting millions in the U.S. The potential for an oral GLP-1 agonist that does not require food or fluid restrictions could offer a more convenient treatment option compared to current injectable therapies. This could improve patient adherence and outcomes, particularly for those who face challenges with injectable treatments. AstraZeneca's progress in this area could also intensify competition in the GLP-1 market, currently dominated by Novo Nordisk and Eli Lilly, potentially leading to more treatment options and better pricing for patients.
What's Next?
AstraZeneca plans to proceed with phase 3 trials, which will include dose-escalation regimens to enhance tolerability. The EMBOLD and ELUMINATE programs will explore elecoglipron as a monotherapy and in combination with other treatments like Farxiga. These trials will also assess long-term cardiovascular and kidney outcomes, which could further establish elecoglipron's role in managing obesity and diabetes. The results of these trials will be crucial in determining the drug's market potential and its ability to compete with existing GLP-1 therapies.
